Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerasespecific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-S/hep)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerasespecific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon neoplasm with an annual estimated incidence of 2000-3000 new cases in the United States (Connelly et al., 1987; Price, 1997) . In more than 70% of patients, the origin of the tumor is linked to a history of exposure to asbestos fibers (Chahinian et al., 1982; Chailleux et al., 1988) . The use of asbestos in Japan increased rapidly after the 1950s and remained at a high level even as the worldwide use of asbestos decreased substantially after the 1980s, therefore, the mortality rate for MPM is expected to continuously increase in Japan (Murayama et al., 2006) . MPM is characterized by progressive local tumor invasion and poor median survival ranging from 9 to 16 months (Ruffie et al., 1989) . MPM is notoriously refractory to treatment, and neither surgery nor radiotherapy alone results in increased survival (Ball and Cruickshank, 1990; Rusch et al., 1991) . Although many chemotherapeutic regimens have been suggested, a standard treatment strategy for MPM remains elusive (Alberts et al., 1988; Ryan et al., 1998) . Therefore, the development of novel therapeutic options is required.
Clinical trials of patients with MPM have established the safety of the intrapleural delivery of replicationdeficient adenoviral vectors expressing the suicide gene, herpes simplex thymidine kinase, followed by the administration of ganciclovir, an antiviral drug. Some evidence indicates that this approach induces an effective antitumor immune response (Sterman et al., , 2005 MolnarKimber et al., 1998) . Moreover, intrapleural interferongene transfer with a replication-defective adenoviral vector may potentially be a useful approach for the generation of antitumor immune responses in MPM patients (Sterman et al., 2007) . A significant obstacle to these approaches is the limited distribution of the non-replicative vectors within the tumor mass, even after direct intratumoral administration. Histopathological analyses have shown that these vectors transduce only a few tumor cells, despite the successful antitumor responses. Therefore, more efficient strategies for the virus to spread within tumors may be required to increase the clinical benefit.
Replication-selective, tumor-specific viruses present a novel approach for the treatment of neoplastic diseases. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is a critical step in carcinogenesis, and it correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector Telomelysin) , in which the hTERT promoter element drives expression of the E1A and E1B genes linked with an internal ribosome entry site. OBP-301 replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity Taki et al., 2005) . In this study, we examined the therapeutic potential of intrapleural delivery of OBP-301 against human MPM tumors intrathoracically implanted into nu/nu mice. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy.
Results
Expression of CAR and hTERT levels in human mesothelioma cell lines To examine the biological characteristics of human mesothelioma cells, we first used flow cytometry to determine the cell surface expression of coxsackie and adenovirus receptor (CAR). CAR was expressed in all four cell lines tested, although the expression levels varied (Figure 1b ). H2052 and H2452 cells showed low, (Tango et al., 2004; Taki et al., 2005) . A real-time reverse transcription-PCR method showed that all cell lines expressed detectable levels of hTERT messenger RNA (mRNA), suggesting that the hTERT promoter element can be used to target human mesothelioma cells (Figure 1c ).
In vitro cytopathic efficacy of OBP-301 on human mesothelioma cell lines To determine whether OBP-301 infection induces selective cell lysis, mesothelioma cells were infected with OBP-301 at various multiplicity of infections (MOIs), and then the XTT cell viability assay was performed over 5 days. All mesothelioma cell lines were efficiently killed by OBP-301 in a dose-dependent manner ( Figure 2 ). Infection at an MOI of 10 was sufficient to induce cell lysis within 3 days. To visually confirm the viral replication and spread, we modified OBP-301 to express the green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus promoter in the E3 region (modified virus, OBP-401) ( Figure 1a) . We have confirmed earlier that the propagation and yields of OBP-301 and OBP-401 are equivalent Kishimoto et al., 2006) . After OBP-401 infection, phase-contrast images showed a rapid loss of viability because of massive cell death, as evidenced by ballooning and floating cells. We observed a strong and persistent GFP fluorescence expression in these mesothelioma cells under a fluorescence microscope, indicating the viral replication and spread into the neighboring tumor cells (Figure 3a) .
Intrathoracic virus spread and infection in an orthotopic pleural human mesothelioma model
We also evaluated the viral infection and replication in human mesothelioma cells growing intrathoracically in athymic nu/nu mice. When H2052 and H2452 mesothelioma cells were inoculated into the thoracic space, disseminated tumor nodules were detected in the visceral pleura, parietal pleura, diaphragmatic pleura and mediastinum. We used H2452 cells with low CAR and hTERT mRNA expression that were considered to be most refractory to OBP-301 for the further in vivo experiments. Tumor weights at autopsy more than 40 days after tumor cell inoculation were significantly greater than tumor weights at o30 days, indicating the tumor growth in the thoracic cavity (Supplementary Figure 1) . Optical charged-coupled device imaging detected GFP-labeled tumors at the gross level during a midsternal thoracotomy 6 days after intrathoracic injection of 1 Â 10 8 plaque-forming units (PFU) of OBP-401. Moreover, GFP expression in macroscopically invisible tumors could be detected at the microscopic level with a hand-held flexible probe inserted through (Figure 3c ). These results suggest that intrathoracically injected oncolytic virus can infect and selectively replicate in disseminated tumor tissues.
In vivo antitumor effect of intrathoracic delivery of OBP-301 in an orthotopic pleural human mesothelioma model To examine the therapeutic effect of telomerase-specific oncolytic virus, mice received an injection of 1 Â 10 7 or 1 Â 10 8 PFU of OBP-301, 1 Â 10 8 PFU of replicationdefective control adenovirus (dl312), or phosphatebuffered saline into the thoracic spacethe injections were administered twice at a 1-week interval beginning 24 h after tumor cell inoculation. Injection of 10 8 PFU of OBP-301 significantly reduced the incidences of tumor cell dissemination and the total weights of tumor nodules as compared with mice that received dl312 or phosphate-buffered saline injection, although 10 7 PFU of OBP-301 had no apparent effect (Figures 4a and b) . Next, we examined treatment schedules with different starting points. Two injections of 1 Â 10 8 PFU of OBP-301 administered at a 1-week interval starting on day 1, 8, 22 or 29 after tumor inoculation showed statistically significant antitumor effects when mice were killed on day 43 (Figure 4c and Supplementary Figure 3) . These results suggest that oncolytic virotherapy could be Enhanced antitumor effect of OBP-301 in combination with heparanase-expressing adenovirus in an orthotopic pleural human mesothelioma model To further enhance the in vivo therapeutic potential of telomerase-specific virotherapy, we examined the combination effect of OBP-301 and a replication-defective adenovirus vector expressing the human heparanase gene (Ad-S/hep) (Uno et al., 2001) . Heparan sulfate is a major constituent of the ECM that is responsible for a barrier to macromolecular diffusion in tumors. Thus, heparanase-mediated ECM degradation may be a critical requisite for virus penetration and distribution into tumor tissues. Western blot analysis revealed the expression of both proheparanase (Mr 65 000) and cleaved, active heparanase (Mr 50 000) in H2542 cells after Ad-S/hep infection expression of these proteins was not affected by the presence of OBP-301 (Figure 5a ). In addition, an in vitro XTT analysis showed that coinfection of Ad-S/hep at various MOIs did not affect OBP-301-mediated cytotoxicity on human mesothelioma cells (Supplementary Figure 4) . We next examined whether heparanase expression enhanced the virus penetration into three-dimensional tumor structures using a human mesothelioma spheroid model. Tumor spheroids provide an excellent in vitro three-dimensional model resembling in vivo tumor masses for visualizing the dynamics of the virus and ) were inoculated into the thoracic space of athymic nu/nu mice. After 24 h, either 1 Â 10 7 plaque-forming units (PFU)/100 ml or 1 Â 10 8 PFU/100 ml of OBP-301, 1 Â 10 8 PFU/100 ml of dl312 (replication-deficient adenovirus), or phosphate-buffered saline (PBS) were injected into the thoracic space twice at a 1-week interval (total dose: 2 Â 10 7 or 2 Â 10 8 PFU). Eight weeks after tumor cell inoculation, the mice were killed, and the pleural dissemination of the thoracic spaces was assessed. Dual virotherapy for malignant mesothelioma Y Watanabe et al assessing the levels of virus penetration. Sequential confocal fluorescent microscopy showed that OBP-401 could penetrate and express GFP fluorescence in H2452 spheroids; GFP expression, however, could be detected in the deeper areas of the spheroids in the presence of Ad-S/hep (Figure 5b, c) . High-magnification images showed that GFP signals were detected only at the spheroid surface after OBP-401 and control dl312 exposure, whereas co-infection of Ad-S/hep enhanced the OBP-401 penetration, leading to GFP expression in multiple layers.
Finally, we assessed the combination effect of OBP-301 and Ad-S/hep in an orthotopic pleural human mesothelioma model. Intrathoracic injection with 1 Â 10 8 PFU of OBP-301 plus 1 Â 10 7 PFU of Ad-S/ hep on days 8 and 15 resulted in a significant reduction of tumor weights on day 43 (Figure 6a ). This combination therapy showed greater antitumor effects than the therapy with 10 8 PFU of OBP-301 alone. The administration of Ad-S/hep alone did not affect tumor weights as compared with the tumors in the mock-treated group. Moreover, only one of the seven (14.3%) mice injected with OBP-301 alone survived over a 12-week observation period, whereas five of the seven (71.4%) mice treated with OBP-301 plus Ad-S/hep remained alive (Figure 6b ).
Discussion
Malignant pleural mesothelioma is an aggressive neoplasm with a dismal prognosis because of its resistance to therapeutic modalities such as chemotherapy and radiotherapy. An alternative therapeutic option is the use of gene-and vector-based therapies. MPM is characterized by intrathoracic spread, and it is clinically accessible, making it an attractive target for locoregional delivery of genetically engineered viral agents. Replication-competent viral agents can confer specificity of infection and increase viral spread to neighboring tumor cells. Onyx-015, a conditional replication-competent adenovirus lacking the 55-kDa E1b gene, may be an effective treatment for human mesothelioma cells retaining wild-type p53 but lacking p14 ARF (Ries et al., 2000; Yang et al., 2000 Yang et al., , 2001 , the targets of Onyx-015, however, are not general and its clinical trials for various types of human malignancies have been discontinued (Goodrum and Ornelles, 1998) . In this study, we showed that intrathoracic administration of telomerase-specific oncolytic viruses induced significant antitumor effects against both pre-established and established pleural dissemination of human MPM. Moreover, we found that co-infection of oncolytic adenoviruses with non-replicative adenovirus expressing an ECM-digestive enzyme, heparanase, resulted in a virus distribution into the deeper areas of tumor spheroids, with substantial tumor weight reduction and enhanced efficacy in an orthotopic in vivo mesothelioma model.
For the success of gene-and vector-based therapies, it is critical to develop strategies to improve the vector distribution within tumors in vivo. Oncolytic viruses can mediate infected cell death, release viral progeny for propagation of infection and induce resultant lysis of neighboring tumor cells. Therefore, these viruses should have a more profound therapeutic efficacy even without particular therapeutic genes when compared with nonreplicative viral vectors. Indeed, as human malignant mesothelioma cells express sufficient telomerase activity as well as CAR (Figure 1) , most of the disseminated nodules were imaged with GFP fluorescence by intrathoracic administration of GFP-expressing, telomerase-specific OBP-401 in an orthotopic pleural mesothelioma model, which coincided with histologically confirmed mesothelioma (Figure 3) . We have recently shown that this OBP-401-mediated GFP-labeling strategy is extremely sensitive to detect disseminated nodules and applicable for the surgical navigation (Kishimoto et al., 2009) . A confocal fluorescent imaging system with fibered microprobes showed that OBP-401 could also identify macroscopically invisible tumor tissues, suggesting that OBP-301 might be able to eliminate microscopic dissemination. In fact, local administration of OBP-301 into the thoracic cavity significantly suppressed the disseminated tumor growth (Figure 4) . The treatment immediately after mesothelioma Dual virotherapy for malignant mesothelioma Y Watanabe et al cell inoculation resembles the state of a minimum residual disease after extended surgical excision. Most of the floating mesothelioma cells could be efficiently treated by locoregional OBP-301 administration, resulting in little disseminated tumor nodule formation. Tumor weights, however, increased gradually as the treatment time was delayed (Figure 4c ), suggesting that some additional approaches are required to improve the therapeutic efficacy.
Extracellular matrix is a major barrier to macromolecular transport in the tumor interstitium, but digestive enzymes that degrade ECM may overcome the limited spread of viral agents within tumors. Previous studies have shown that protease that degrades multiple ECM components as well as collagenase that digests fibrillar collagen can mediate a broad distribution of virus particles within tumors, leading to enhanced therapeutic efficacy (Kuriyama et al., 2001; McKee et al., 2006) . Non-replicating adenovirus vector expressing the matrix metalloproteinase-8 (MMP-8), which effectively degrades collagen-I, was also able to modify a fibrillar collagen substrate to allow oncolytic virus diffusion into tumors (Cheng et al., 2007) . More recent studies have also shown that relaxin-expressing, replication-competent adenovirus could increase the virus distribution and show a profound antitumor effect in mice (Kim et al., 2006; Ganesh et al., 2007) . Although the most effective enzyme for the promotion of viral penetration into tumor masses has not been determined, we used heparanase, which has a hydrolytic mechanism to cleave glycosidic bonds in the heparan sulfate component of the ECM (McKenzie, 2007) .
The expression of functional heparanase degrades the ECM, which in turn improves the uptake and distribution of biological agents including antibodies and viruses (Eikenes et al., 2004 ). An advantage of heparanase is that other enzymes that are capable of digesting ECM and basement membrane components (such as MMP-2 and MMP-8) can be subsequently induced after heparanase expression. We reported earlier that the over-expression of the heparanase gene upregulated MMP-2 mRNA expression in human lung cancer cells (Uno et al., 2001) . Arterial injury also increased heparanase activity in vascular endothelial cells, which was associated with MMP-2 and MMP-9 activation (Fitzgerald et al., 1999) . Therefore, a more prominent virus infiltration through broad ECM degradation with multiple enzymes can be expected by exogenous heparanase expression. The co-infection of Ad-S/hep considerably enhanced OBP-401 virus penetration into the multicellular spheroids, mimicking the in vivo biology of tumors (Figure 5b, c) . Furthermore, combination therapy with OBP-301 and Ad-S/hep in an orthotopic murine model significantly reduced the tumor weights of disseminated plural mesothelioma as compared with tumors from mice treated with OBP-301 alone (Figure 6a ), suggesting that heparanase-assisted broad virus distribution could mediate a more profound antitumor effect against human malignant mesothelioma.
Our data indicate that this dual virotherapy may be a promising therapeutic strategy for malignant pleural mesothelioma. However, the over-expression of ECMdigesting enzymes may potentially promote the metastasis of tumor cells. MMPs as well as heparanase were detected in many types of human cancer, and their expression has a very active role in tumor invasion and metastasis. Indeed, targeted inhibition of heparanase expression by antisense complementary DNA transfection showed a significant reduction in the invasive and metastatic properties of tumor cells in an animal model (Uno et al., 2001 ). Short hairpin RNAs that mediated the attenuation of MMP expression also prevented the progression of human tumor cells in vivo (Blackburn et al., 2007) . Although there is a risk that the metastatic potential of tumor cells may be increased by heparanase expression, we found that the intrathoracic administration of 10 7 PFU of Ad-S/hep alone had no apparent effects on the growth of pleural mesothelioma, indicating that this particular dose of the virus appears to be safe (Figure 6a ). In the dual-vector system, the two viral loads can be adjusted according to the function of each virus. We showed earlier that telomerase-specific oncolytic viruses and non-replicative adenovirus-expressing functional genes can successfully work together by determining the optimal doses of vectors Hioki et al., 2008) . A single oncolytic virus vector-expressing relaxin inhibits tumor growth and metastasis, however, it may be impossible to reduce the amount of relaxin expression when high doses of the virus are used. In contrast, our dual-vector system of telomerase-specific oncolytic adenovirus in combination with heparanase-expressing replication-deficient adenovirus can be used safely by a fine adjustment of the optimal doses.
In conclusion, our data clearly indicate that telomerase-specific oncolytic adenoviruses have significant therapeutic potential against human malignant pleural mesothelioma in vitro and in vivo. Moreover, the addition of heparanase-expressing adenovirus significantly enhanced the virus distribution and the antitumor effects of oncolytic adenoviruses. A phase I, doseescalation study of telomerase-specific oncolytic adenovirus, OBP-301, is currently underway in the United States to assess the treatment feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors . Phase II studies of telomerase-specific virotherapy in malignant pleural mesothelioma patients are warranted.
Materials and methods

Cell lines and culture conditions
The human mesothelioma cell lines H2052, H2452, H28 and 211H were purchased from American Type Culture Collection (Manassas, VA, USA). H2052 and H2452 cells were cultured as monolayers in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. H28 and 211 H were routinely propagated in monolayer culture in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 mg/ml streptomycin. The human non-smallcell lung cancer cell line H1299 was also cultured in RPMI Recombinant adenoviruses OBP-301 is a telomerase-specific replication-compenent adenovirus variant, in which the hTERT promoter element drives the expression of E1A and E1B genes linked with internal ribosome entry site (Figure 1a ). OBP-301 was modified to create OBP-401 for monitoring viral replicationthe GFP gene was inserted under the cytomegalovirus promoter into the E3 region to create OBP-401. Ad-S/hep is a replication-deficient adenovirus expressing the human heparanase gene under the cytomegalovirus promoter. The E1A-deleted adenovirus dl312 was used as the control adenovirus.
Flow cytometric analysis A total of 2 Â 10 5 cells were labeled with mouse monoclonal anti-CAR (RmcBUpstate Biotechnology, Lake Placid, NY, USA) for 30 min at 4 1C. Then, the cells were incubated with fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG second antibody (Zymed Laboratories, South San Francisco, CA, USA) and analysed by flow cytometry (FACSCalibur, Becton Dickinson, Mountain View, CA, USA). An isotypematched normal mouse IgG 1 conjugated to fluorescein isothiocyanate (Serotec, Oxford, UK) was used as a control.
Quantitative real-time PCR analysis of hTERT mRNA Total RNA from the culture cells was obtained by using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). Approximately 0.1 mg of total RNA was used for reverse transcription. Reverse transcription was performed at 22 1C for 10 min and then at 42 1C for 20 min. The hTERT mRNA copy number was determined by real-time quantitative reverse transcription-PCR using a LightCycler instrument and a LightCycler DNA TeloTAGGG hTERT Quantification Kit (Roche Molecular Diagnostics, Indianapolis, IN, USA). Data analysis was performed using the LightCycler software. The ratios normalized by dividing the value of untreated cells were presented for each sample.
Cell viability assay
The XTT assay was performed to measure cell viability. Briefly, cells were seeded at 1 Â 10 3 cells/well in 96-well plates 16-20 h before viral infection and infected with OBP-301 at a MOI of 0, 1, 10 or 50 PFU/cell. Cell viability was determined at the indicated times by using a Cell Proliferation Kit II (Roche Applied Science, Mannheim, Germany) according to the manufacturer's protocol.
Fluorescent microscopy
Human mesothelioma cell lines were infected with 10 MOI of OBP-401 in vitro. Expression of the GFP gene was assessed and photographed using an IX71 fluorescent microscope (Olympus, Tokyo, Japan) at indicated times.
Western blot analysis H2452 cells were collected by trypsinization and washed twice in cold phosphate-buffered saline. Cells then were dissolved in lysis buffer containing 50 mM Tris-HCl (pH7.5), 150 mM NaCl, 0.5% Triton X-100, and protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM 4-(2-aminoethyl)benzenesul-fonylfluoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin, and 1 mg/ml aprotinin).The lysis was performed at 4 1C for 30 min, and then the reaction mixture was centrifuged at 15 000 revolutions per minute. The protein concentration of the supernatant was determined by using the Bio-Rad protein determination method (Bio-Rad, Hercules, CA, USA). Equal amounts (60 mg) of proteins were electrophoresed under reducing conditions on 12% (w/v) polyacrylamide gels. Proteins were electrophoretically transferred to Hy-bond-polyvinylidene diflouride transfer membranes (Amersham, Arlington Heights, IL, USA) and incubated with primary antibodies against heparanase or b-actin, and then peroxidase-linked secondary antibody. An enhanced chemiluminescence Western system (Amersham, Tokyo, Japan) was used to detect secondary probes.
Spheroid culture
Single-cell suspensions of H2452 cells were obtained by trypsinization of monolayer cultures that consisted of 1 Â 10 4 cells seeded on SUMILON Celltight Spheroid (Sumitomo Bakelite Co, Tokyo, Japan) according to the manufacturer's protocol. After formation of small spheroidal aggregates, 1 Â 10 3 PFU of Ad-S/hep or dl312 were added to the culture, followed by the addition of 1 Â 10 4 PFU of OBP-401 48 h later. The GFP expression in each tumor spheroid was assessed under the laser-scanning confocal fluorescent microscope (Carl Zeiss, Jena, Germany) 48 h later.
Animal experiments
The experimental protocol was approved by the ethics review committee for animal experimentation of our institution. We used a 27-gauge needle to intrathoracically inject female BALB/c nu/nu mice with 100 ml of suspension containing 5 Â 10 6 H2452 cells. The same technique was used for each viral injection into the thoracic space at the indicated time points. Mice were killed and their thoracic spaces were examined macroscopically. Tumor nodules in the thoracic spaces were removed and weighted. In vivo GFP fluorescence imaging was also acquired by using a Hamamatsu C5810 three-chip color cooled charged-coupled device camera (Hamamatsu Photonics Systems, Hamamatsu, Japan) and an in situ molecular imaging system (CellBVIZIOMauna Kea Technologies, Paris, France).
Statistical analysis
We used the Student's t-test to determine statistically significant differences among the groups. P-values o0.05 were considered statistically significant.
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